Welcome to MetTech on air, your window into the world of medical technologies.

This is a podcast by MedTech Europe, the European Trade Association for the Medical Technology Industry.

My name is Estefania Cordero. I'm the communications manager, and I am the host of this podcast.

In this episode, we're delving into the lifeblood of Europe's medical technology sector, research and innovation.

Through our sector's investment into research and innovation,

we're able to develop life-changing medical technologies and digital health solutions that

set the standard for quality patient care in Europe and beyond. At the same time, there are

ways to build our impact through collaborations known as public-private partnerships. To dive deeper into this today,

we're speaking to Mark Lloyd-Davies. Mark is the global head of the Strategics Partnerships

and Resource Group at Johnson and Johnson, a MedTech Europe member. We've invited Mark to chat

with us today because of his long-standing experience working in collaborative R&I in Europe.

And Mark, we are so pleased to have you in the

podcast today. Welcome. Thank you. Pleasure to be here. Before we dig in, Mark, I'd love for our

listeners to learn a little bit more about you. Can you tell us a little bit about your experience and

what your office looks after at J&J? Absolutely. So I've been at Johnson Johnson for close to 15

years and my team, strategic partnership and resource group or SPRG, we partner with leaders across

Johnson Johnson who essentially want to accelerate their innovation. And we help them accelerate

their innovation or de-risk that innovation or essentially amplify their own internal resources by seeing what external resources are that are available that we can bring into the organization where we're aligned on our goals and purposes.

And these external resources are about primarily people, ideas, innovation, data, networks, and can evolve

an element of financing as well. And the best feedback we get from our senior internal

R&D leaders is that we're able to help them get their products and their ideas to patients

as fast as possible, but in the way which is compliant

...